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Abstract
Background: The search for an optimal experimental model in pharmacology is recently focused
on (mini)pigs as they seem not only to be an alternative source of cells and tissues for xenotherapy
but also an alternative species for studies on drug metabolism in man due to similarities between
(mini) pig and human drug metabolizing systems. The purpose of this work is to characterize
minipig liver microsomal cytochromes P450 (CYPs) by comparing their N-terminal sequences with
corresponding human orthologs.
Results: The microsomal CYPs exhibit similar activities to their human orthologous enzymes
(CYP3A4, nifedipine oxidation; 2A6, coumarin 7-hydroxylation; 2D6, bufuralol 1'-hydroxylation;
2E1, p-nitrophenol hydroxylation; and 2C9, tolbutamide hydroxylation). Specific minipig CYP (2A,
2C and 3A) enzymes were partially purified and proteins identified by immunostaining (using
antibodies against the respective human CYPs) were used for N-terminal amino acid sequencing.
From comparisons, it can be concluded that the sequence of the first 20 amino acids at the N-
terminus of minipig CYP2A is highly similar to human CYP2A6 (70% identity). The N-terminal
sequence of CYP2C shared about 50% similarity with human 2C9. The results on the minipig liver
microsomal CYP3A yielded identical data with those obtained for amino acid sequences of the pig
CYP3A29 showing 60% identity with human CYP3A4.
Conclusions: Thus, our results further support the view that minipigs may serve as model animals
in pharmacological/toxicological studies with substrates of human CYP enzymes, namely, of the
CYP3A and CYP2A forms.
Background
Cytochromes P450 (EC 1.14.14.1, CYP) enzymes are
known to metabolize the majority of drugs, to detoxify
environmental pollutants as well as to activate some
classes of carcinogens as polycyclic aromatic hydrocar-
bons or nitrosamines [1–3].
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Detoxifying systems of minipig and pig liver have recent-
ly attracted considerable attention [4–8] as the minipig
and pig liver and hepatocytes are believed to be a possi-
ble solution for construction of bioartificial liver devices
designed to overcome the shortage of human organs for
transplantation [7,9]. Moreover, pigs and especially min-
ipigs might be good model species for general studies in
pharmacology and toxicology without the need to induce
biotransformation enzymes [10]. Minipig and pig liver
have been shown to express the main biotransformation
enzymes in amounts and activities comparable to their
human counterparts [4,6–8,11]. Three cDNA clones
from a porcine small intestine cDNA library were identi-
fied as transcripts of three members of porcine CYP gene
subfamily, CYP2D25, CYP3A29, and truncated
CYP2C42; the fourth cDNA clone appeared to encode a
putative CYP2C pseudogene [12,13].
An advantage of the minipig is that it is apparently close
to the conventional pig and, hence, the properties of the
drug metabolizing systems should be very similar. In our
previous work, we have found CYP1A, 2A, 2C, 2D, 2E,
and 3A marker activities in minipig liver microsomes by
testing the respective specific substrates for human CYP
enzymes [4]. In this paper, we report the results of the
isolation and characterisation of the first three CYP en-
zymes from minipig liver microsomal fraction belonging
according to their activities as well as to their N-terminal
amino acid residues to the CYP2A, CYP2C, and CYP3A
subfamilies.
Results and discussion
The microsomal fraction of minipig liver homogenate
has been shown to contain the activities characteristic of
human CYP3A4 (nifedipine oxidation), 2A6 (coumarin
7-hydroxylation), 2D6 (bufuralol 1'-hydroxylation), 2E1
(p-nitrophenol hydroxylation), and 2C9 (tolbutamide
hydroxylation) [4]. The presence of these CYP enzymes
in minipig microsomes was confirmed by immunoblot-
ting using antibodies against the respective human P450
enzymes (results not shown). These results have con-
firmed our earlier finding [4] as well as the results of oth-
er authors on pig [6,7,14] and minipig liver microsomal
systems [8,15].
The isolation procedure led to fractions containing par-
tially purified CYP enzymes in which the specific activi-
ties of CYP3A and 2A forms were detected, the activity of
the CYP2C enzyme in the partially purified sample was
not estimated as it has been consumed by experiments
aimed at characterisation of selected proteins. The main
purpose of this work was to obtain partially purified
preparations, confirm the presence of selected CYP pro-
tein forms in them and with help of electrophoresis and
immunoblotting to detect the corresponding CYP pro-
teins. Subsequently, to use the identified CYP forms for
N-terminal protein sequencing. Specific minipig CYP en-
zymes in the enriched fractions were visualised by im-
munostaining with cross-reacting polyclonal antibodies
raised against particular human CYP enzymes (Fig.
1A,B,C). The bands on the blots stained for total protein
by Coomassie Blue R-250 corresponding by their posi-
tion to migration of purified human isoforms and yield-
ing also the bands by immunostaining, in other words,
identified this way to correspond to the respective hu-
man enzyme, were excised and subjected to N-terminal
sequencing. This approach allowed identification of the
Figure 1
Immunoblotting of enriched samples of minipig CYPs Lane 1:
1 pmol of the respective CYP standard; lanes 2 and 3:
CYP3A-rich fractions, 5 pmol; lanes 4 and 5: CYP2A- and
2C-rich fractions, 12.5 pmol applied per lane onto 8% gel.
Blot development: A – 100 µg of anti 2A6 IgG; B – 50 µg of
anti 2C9 IgG; C – 50 µg of anti 3A4 IgG.BMC Pharmacology 2001, 1:11 http://www.biomedcentral.com/1471-2210/1/11
first 20 amino acids from N-terminus of minipig CYP
corresponding to human CYP2A6, 18 amino acids from
N-terminus of minipig CYP corresponding to human
CYP2C9, and 20 amino acids from N-terminus of mini-
pig CYP corresponding to human CYP3A4. N-Terminal
amino acid sequences or 5'-end cDNA sequences of pig
or minipig CYP2A and CYP2C have not been published to
date, therefore, we compared our results directly with
the known human CYP2A6 and 2C9 sequences (Table 1).
From this comparison it can be concluded that the N-ter-
minus of minipig CYP2A is highly similar to human
CYP2A6 (14 of 20 amino acids identical). Comparison of
CYP2C family members may be quite difficult because of
very high content of Leu at the N-terminus of the se-
quenced minipig protein (still about 50% sequence iden-
tity with the human counterpart, Table 1). Moreover, the
human CYP2C subfamily has at least four highly homol-
ogous clones (sequence identity at the N-terminus >
90%), and therefore the existence of other CYP2C-relat-
ed genes in the minipig may be anticipated. This problem
may hamper further attempts to identify minipig CYP2C
proteins with the approach we have used. cDNA cloning
should help to answer this question much better.
The protein sequence of another CYP protein present in
the sample matched very well the N-terminal amino acid
sequence deduced from published cDNA for pig
CYP3A29 (Table 1, data from [13]). The pig/minipig
CYP3A and human CYP3A4 shared about 60% sequence
similarity (12 of 20 amino acids identical). The presence
of a minipig liver CYP3A enzyme with similar activities to
the human CYP3A4 has been reported earlier [4]. To-
gether with the data obtained with pig liver and intesti-
nal microsomal systems [16–18], the results support the
suitability of pigs/minipigs for modeling the biotransfor-
mation of drugs in man.
From our results it seems that pigs and minipigs have
CYP2A, 2C, and 3A liver microsomal enzymes with very
similar N-terminal sequences to the human enzymes.
This finding may be important for pharmacological and
toxicological studies because i) CYP3A, 2C and 2A en-
zymes metabolize many known industrial chemicals and
drugs in human use and ii) minipigs in pharmacology/
toxicology are much easier to handle than conventional
pigs as model animals. The observed high similarities of
N-terminal sequences of minipig and human CYP2A and
2C confirm the previously published similarity in marker
activities [4,8].
Conclusions
The results presented in this study support the use of
minipigs as experimental animals to predict biotransfor-
mation pathways in man and should stimulate further
research on similarity of structure and substrate specifi-
city of individual human and (mini)pig CYP enzymes.
The conclusions then obtained may in future bring justi-
fication for the use of pig hepatocytes and liver for extra-
corporeal detoxification and xenotransplantation.
Materials and methods
Chemicals
All reagents and chromatographic materials were pur-
chased from Sigma-Aldrich (Prague, CR) if not stated
otherwise and were of the analytical grade purity. DEAE
Sephacel was product of Pharmacia Biotech (Uppsala,
Sweden). Polyclonal rabbit anti-CYP2A6, anti-CYP2C9,
and anti-CYP3A4 IgG were prepared as described else-
where [19]. Human recombinant CYP2A6, 2C9, and 3A4
were expressed in Escherichia coli and purified as de-
scribed previously [20–22] and used as standards.
Purification of minipig enzymes
Microsomal fractions of liver homogenates were pre-
pared from minipig livers (Brno white variety of Goettin-
gen minipig, Research Institute of Veterinary Medicine,
Brno, CR, 25–30 kg body weight, male castrates, N = 5,
age 6 months). No induction protocols were applied to
minipigs. The preparation of microsomes was done ac-
cording to standard procedure [23]. Separation of CYP
enzymes from cholate-solubilized microsomal fraction
was based in general on the procedure developed earlier
[24,25]. Solubilized microsomes were applied to an oc-
tyl-Sepharose column where the NADPH-cytochrome
P450 reductase was eluted first during the wash with
Table 1: Comparison of Human, Pig, and Minipig CYP N-terminal 
sequences
Gene Sequence (amino acid No.)
11 0 2 0
Minipig CYP2A M L A S G L L L V A L L T/L R L X I F V L
Human CYP2A6a M L A S G ML L V A L L V C L T V M V L
11 0 1 8
Minipig CYP2C M D V L V X L A L X L L L V X L L L
Human CYP2C9b M D S  L V V L V L C L S C L L  L L S
11 0 2 0
Minipig CYP3A M D L I P G F S T E T W V L L A T S L V
Pig CYP3A29c M D L I P G F S T E T W V L L A T S L V
Human CYP3Ad M A  L I P D L A M E T  R  L  L L A V S L V
Notes: X – amino acid was not identified. Similarities between pig and 
minipig cDNAs in bold. GeneBank accession numbers: aAF182275, 
bM61855, cZ93099, dAF209389BMC Pharmacology 2001, 1:11 http://www.biomedcentral.com/1471-2210/1/11
equilibration buffer (buffer A, 0.1 M K/PO4, pH 7.25, 1
mM EDTA, 20% (v/v) glycerol, 0.6% (w/v) cholate), in
which the cholate concentration was reduced to 0.42%. A
sharp peak containing cytochrome b5 together with
CYP3A was eluted when the concentration of cholate was
further lowered to 0.33% and 0.06% (w/v) Triton N-101
was added to buffer A. The next fractions eluted after
CYP3A and cytochrome b5 appeared to contain mainly
the CYP2C and CYP2D enzymes. Lastly, the fractions
with CYP2A were eluted. CYP3A was separated from cy-
tochrome b5 by anion exchange chromatography on
DEAE Sephacel equilibrated with buffer B: 5 mM K/PO4,
pH 7.7, containing 0.1 mM EDTA, 20% glycerol (v/v),
and 0.2% sodium cholate (w/v). Increasing the cholate
concentration to 0.5% along with addition of 0.2% Triton
N-101 (w/v) resulted in elution of the CYP containing
peak. Impure fractions containing CYP were dialyzed
overnight against 10 mM potassium phosphate, pH 7.4,
containing 0.05 mM EDTA, 0.1 mM dithiothreitol, and
20% glycerol (v/v) and further purified by chromatogra-
phy on a hydroxylapatite column equilibrated with the
same buffer. Extensive washing was done to remove Tri-
ton N-101. CYP was eluted using a linear gradient of
phosphate, from 10 mM to 500 mM. The hydroxylapatite
chromatography was repeated to further purify the CYP
enzyme fractions prior to immunoblotting and amino
acid sequencing.
Activity assays
The results of activity assays are displayed in Table 2.
Nifedipine oxidation was followed to characterize the
CYP3A enzyme activity according to [26]. Oxidation of
nifedipine was determined in microsomes as well as in
fractions after chromatography. In this case, a reconsti-
tuted system including 200 pmol of NADPH-cytochrome
P450 reductase (PanVera, Madison, WI) was used with a
procedure described previously [21]. Coumarin 7-hy-
droxylation was followed to estimate the CYP2A activity
[27]. To monitor the activity of CYP2C enzyme(s), in mi-
crosomal faction, tolbutamide hydroxylation was deter-
mined [28]. The determination of activities in fractions
containing partially purified CYP enzymes was done in
systems mimicking the original microsomal prepara-
tions with addition of components lost during the proc-
ess of purification of CYP enzymes (NADPH:cytochrome
P450 reductase, cytochrome b5, phospholipid). The
method was based on general approach described by Shi-
mada and Yamazaki [29].
Electrophoresis and immunoblotting
SDS electrophoresis was done in 10% and 8% (w/v) poly-
acrylamide gels by the method of Laemmli [30] using a
MiniProtean apparatus (BioRad, Hercules, CA). Protein
staining was done with Coomassie Blue R-250 [31] and
immunoblotting was performed as described [32] using
the described conditions for development of blots [19].
Polyclonal anti-human CYP2A6, 2C9 and 3A4 IgG were
used.
Amino acid sequencing
N-Terminal amino acid sequencing was performed using
Procise Protein Sequencer (Applied Biosystems, Foster
City, CA) and methodology based on Edman degrada-
tion. SDS electrophoresis, transfer of protein to Immo-
bilon-P membrane (Millipore Corp. Bedford, MA), and
staining methods are described elsewhere [19]. Yields at
each cycle were estimated by comparison with external
standards.
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